Preclinical Pipeline
Autoimmune Diseases
Key Facts
About Autolus Therapeutics
Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.
View full company profileAbout Autolus Therapeutics
Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.
View full company profileAbout Autolus Therapeutics
Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation & Immunology Programs | Pfizer | Phase 2/3 |
| ARGX-118 | Argenx | Phase 1 |
| Adalimumab biosimilar (IBI303) | Innovent Biologics | Approved |
| Hulio (Adalimumab) | Biocon | Approved |
| Undisclosed ImmTAAI candidates | Immunocore | Preclinical |
| BHV-1100 (IgG degrader) | Biohaven | Preclinical |
| Bispecifics | Shattuck Labs | IND-Enabling |
| FT839 | Fate Therapeutics | Phase 1 |
| IMP761 | Immutep | Phase 1 (planned) |